



By Carolyn Gretton

### ► PHARMACEUTICAL POOL

**Steve FRY**  
**Dr. Sue MAHONY**

#### LILLY ANNOUNCES LEADERSHIP SHIFTS



Lilly has promoted Steve Fry to senior VP of human resources and diversity. Mr. Fry was previously VP of human resources for two of Lilly's business areas, biomedicines and emerging markets.



Mr. Fry succeeds Sue Mahony, Ph.D., who has been elevated to senior VP and president of Lilly Oncology.

Ms. Mahony has been with Lilly for more than 10 years and was appointed VP of human resources in 2009. She received a Ph.D. in pharmacy in the cancer research campaign experimental chemotherapy group from Aston University in the United Kingdom, and an MBA from London Business School.

**Dr. Yvonne GREENSTREET**

#### PFIZER SELECTS GSK VETERAN AS SPECIALTY CARE DEVELOPMENT HEAD



Pfizer has appointed Yvonne Greenstreet senior VP and head of medicines development for the specialty care business unit. Dr. Greenstreet has global responsibility for leading the advancement of the development portfolio and ensuring its alignment with specialty care's strategic objectives.

Dr. Greenstreet joins Pfizer after an 18-year career with GlaxoSmithKline, where she most recently served as senior VP and chief of strategy, research and development. She holds a degree in medicine from the University of Leeds in the United Kingdom and an MBA from INSEAD in France.

### ► BIOTECHNOLOGY POOL

**Dr. James SHIPLEY**  
**Dr. Robert SILVERMAN**

#### CONCERT PHARMACEUTICALS EXPANDS LEADERSHIP



Concert Pharmaceuticals has appointed James Shipley, M.D., chief medical officer, with responsibility for clinical research and operations, regulatory affairs, quality assurance, and clinical pharmacology.

Concert is a clinical-stage biotechnology company focused on applying the company's



DCE (deuterated chemical entity) platform to create novel and differentiated small-molecule drugs.

Dr. Shipley was previously senior VP of clinical development, medical and regulatory affairs, for Indevus Pharmaceuticals. He received an M.A. in psychology/neuroscience from the University of Western Ontario and an M.D. from the University of Pittsburgh.

In other moves, Concert has promoted Robert Silverman, J.D., Ph.D., to senior VP and general counsel, from VP and general counsel. Dr. Silverman holds a J.D. from Rutgers School of Law Camden and a Ph.D. in organic chemistry from the University of New Mexico.

**Dr. Theresa WINGROVE**

#### IMMUNOGEN APPOINTS REGULATORY VP



ImmunoGen, a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and targeted antibody payload (TAP) technology, has appointed Theresa Wingrove, Ph.D., VP of regulatory affairs.

Dr. Wingrove is responsible for leading the regulatory development of the company's product candidates and directing the regulatory submissions prepared by ImmunoGen in support of its own programs and those of its partners.

Dr. Wingrove joins ImmunoGen from HistoGenics, where she was VP of regulatory and clinical affairs. She earned a doctorate in biochemical toxicology from the University of Rochester.

### ► BIOPHARMACEUTICAL POOL

**Martha CARTER**

#### AEGERION NAMES REGULATORY CHIEF



Aegerion Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, has appointed Martha Carter chief regulatory officer. Ms. Carter was most recently senior VP and chief regulatory officer at Proteon Therapeutics.

**John JOHNSON**

#### FORMER LILLY EXECUTIVE JOINS SAVIENT AS CEO

Savient Pharmaceuticals has named John Johnson CEO. Mr. Johnson most recently served as a senior VP of Lilly and president of Lilly's oncol-



ogy business unit. Savient is a specialty biopharmaceutical company focused on developing and commercializing Krystexxa for the treatment of chronic gout in adult patients refractory to conventional therapy.

**Dr. Steven MILLER**

#### CATALYST PHARMACEUTICAL PARTNERS TAPS OPERATING CHIEF



Catalyst Pharmaceutical Partners, a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting addiction and diseases of the central nervous system, has promoted Chief Scientific Officer Steven Miller, Ph.D., to the additional role of chief operating officer.

Dr. Miller has been with Catalyst since 2007. He received a Ph.D. from the University of Miami.

**Dr. Mario SALTARELLI**

#### FORMER ABBOTT VP JOINS SHIRE'S SPECIALTY BUSINESS



Global biopharmaceutical company Shire has appointed Mario Saltarelli, M.D., Ph.D., senior VP of clinical development and medical affairs of the company's specialty pharmaceuticals business.

Dr. Saltarelli provides overall scientific and professional leadership, as well as clinical and medical strategies, for Shire's global drug development programs.

Dr. Saltarelli was previously with Abbott, where he served as the divisional VP directly accountable for all aspects of clinical development, medical affairs, and development strategy for global neuroscience and anesthesia products.

He received both an M.D. in medicine and a Ph.D. in neuropharmacology from The Johns Hopkins University.

### ► SPECIALTY POOL

**Ted WHITE**

#### FORMER NOVARTIS EXECUTIVE JOINS AQUA PHARMACEUTICALS



Aqua Pharmaceuticals, a specialty pharmaceutical company focusing on acquiring, developing, and marketing prescription dermatology products, has named Ted White as VP, sales, with responsibility for the management of Aqua's rapidly growing sales force.

Mr. White was previously managing director at Novartis. He received an MBA with an emphasis in pharmaceutical marketing from St. Joseph's University.

## ▶ DRUG-DELIVERY POOL

### Paul DAVIS

#### Jared HAHN

#### AVEVA DDS EXPANDS BUSINESS DEVELOPMENT TEAM



Aveva Drug Delivery Systems (DDS), a Nitto Denko company, has added to its business development department to support the company's globalization goals and the development of a well-balanced pipeline of transdermal drug delivery systems.



Paul Davis has joined Aveva DDS as director, alliance management. Mr. Davis previously worked in Beckman

Coulter's business development and alliance management group.

He received an MBA from the University of Florida.

Jared Hahn has been appointed marketing manager. Mr. Hahn was previously with Technology Catalysts International.

## ▶ DEVICE/DIAGNOSTIC POOL

### Christine MEDA

#### RESPONSE GENETICS NAMES NEW PRESIDENT



Response Genetics, a company focused on the development and commercialization of molecular diagnostic tests for cancer, has appointed Christine Meda president.

Kathleen Danenberg, who previously held this position, continues as CEO of Response Genetics. Ms. Meda was previously president and CEO of Arcxis Biotechnologies.

### Donald SOUTHARD

#### INFRAREDX APPOINTS CHIEF EXECUTIVE



InfraReDx, a medical device company developing intelligent cardiovascular diagnostic imaging technologies, has named experienced medical device executive Donald Southard president and CEO.

Mr. Southard succeeds Co-Founder James Muller, M.D., who continues as InfraReDx's chair-

man and chief medical officer. Mr. Southard joins InfraReDx from Zonare Medical Systems, where he most recently was CEO.

He received an executive MBA from Babson College.

## ▶ EMERGING POOL

### Dr. Bozena KORCZAK

#### POLYMEDIX PROMOTES DEVELOPMENT CHIEF



PolyMedix, an emerging biotechnology company focused on developing new therapeutic drugs for the treatment of serious infectious diseases and acute cardiovascular disorders, has promoted Bozena Korczak, Ph.D., to senior VP, Drug Development and Chief Development Officer.

Dr. Korczak is responsible for all drug development activities related to PolyMedix's pipeline of products, including clinical development and operations, regulatory affairs, and chemistry, manufacturing, and controls.

She also continues to oversee the company's clinical advisors.

Dr. Korczak joined PolyMedix in November 2007 as VP, drug development. She received a Ph.D. in biochemistry from the Polish Academy of Science.

## ▶ AGENCY POOL

### Marissa ADDALIA

#### Jackie CLEARY

#### Ian COUGHLIN

#### Caroline CUNHA

#### Karla DOUGHERTY

#### Tom FORBES

#### Dmitry GRYTSENKO

#### Erika HEIGES

#### Priya KARNIK

#### Lillian MILLER

#### Michael MOLLOY





#### Jennifer SANTIAGO

#### Lisa WEISBERG

#### Rita WILLIAMS

#### HEALTHED ANNOUNCES STAFF ADDITIONS, PROMOTIONS

HealthEd, a specialized agency focused on turning education into positive health outcomes,



has made a number of additions and promotions to its staff.

Marissa Addalia has been promoted to VP, management supervisor, account services, from management supervisor.

Jackie Cleary was promoted to manager, health education, from health education specialist.

Ian Coughlin has joined HealthEd as project manager, information technology, from the same position at Caggemini.

Caroline Cunha has been promoted to account supervisor, account services, from senior account executive.

Karla Dougherty has been named senior copywriter. Before joining HealthEd, Ms. Dougherty held the same position with Ogilvy CommonHealth and Healthworld Payers Marketing.

Tom Forbes has been promoted to account supervisor, account services, from senior account executive.

Dmitry Grytsenko has been appointed a senior developer. Mr. Grytsenko previously held senior programmer analyst and developer positions with BluePhoenix Solutions, Wellington Consulting Company, and International Research and Training Center of Information Technologies. He received an M.S. from Kyiv National Taras Shevchenko University in Ukraine.

HealthEd has promoted Erika Heiges to director, health education, from manager, health education.

Priya Karnik has been promoted to director, strategic planning, from senior strategic planner.

Lillian Miller has been promoted to management supervisor, account services, from account supervisor. Michael Molloy has been promoted to art director from junior art director.

Jennifer Santiago has joined HealthEd as senior editor. Ms. Santiago was previously editorial director for Intellisphere.

Lisa Weisberg has been elevated to creative supervisor, copy, from senior copywriter.

Rita Williams has been promoted to manager, health education, from health education specialist.



**Ky ANDERSON**  
**Chad BERNSTEIN**  
**Sarah JENKINS**  
**Caragh REILLY**

**ABELSONTAYLOR ANNOUNCES ACCOUNT TEAM PROMOTIONS**



Independent healthcare advertising agency AbelsonTaylor has announced a number of promotions within its account management team.



Ky Anderson has been promoted to account executive from assistant account executive, with responsibility for products in the infectious diseases (HIV) area. Mr. Anderson has been with AbelsonTaylor since 2008 and has handled account work for products in the areas of oncology, multiple sclerosis, and infant nutrition.



Chad Bernstein has been promoted to account executive from assistant account executive. Mr. Bernstein, who joined AbelsonTaylor in 2008, is working on a product for the treatment of cholesterol.

Sarah Jenkins has been promoted to senior account supervisor from account supervisor. Ms. Jenkins, who has been with the agency since 2005, is spearheading an account for the treatment of insomnia.

Caragh Reilly has been promoted to senior account supervisor from account supervisor, with responsibility for leading the launch of an obesity product.

Ms. Reilly joined AbelsonTaylor in 2006, handling products for the treatment of psoriasis and osteoporosis.

**Lissette CAPATI**

**VP REJOINS SPECTRUM**



Lissette Capati has rejoined independent health and science communications firm Spectrum as VP, responsible for leading several key accounts as well as direct marketing and business development for the agency.

Ms. Capati was most recently with Zeno Group, where she led corporate and scientific communications and social media campaigns for clients in the company's healthcare practice.

**Peter DANNENFELSER**

**TARGETBASE STRENGTHENS STRATEGY TEAM**

Pharmaceutical marketing veteran Peter Dannenfelsler has joined direct marketing agency



Targetbase as VP of strategy, healthcare.

Mr. Dannenfelsler is responsible for leading Targetbase's healthcare practice, cultivating partnerships, and spearheading the integration of emerging channels. He was most recently senior director of marketing communications at Forest Laboratories.

**Tom JONES**

**MAKOVSKY EXPANDS HEALTH PRACTICE**



Biopharma industry consultant Tom Jones has joined the health practice of Makovsky + Company as group VP. Mr. Jones is leading a number of Makovsky's new product assignments and its growing client work in health-digital communications.

**Eric WENSTROM**

**Clifton WONG**  
**PACIFIC COMMUNICATIONS MAKES NEW APPOINTMENTS**



Healthcare agency Pacific Communications has added two staff members to its interactive communications group.



Eric Wenstrom has been named interactive account supervisor. Mr. Wenstrom provides client interface throughout all phases of interactive and digital projects, including assisting with new project opportunities for existing clients.

Mr. Wenstrom was most recently an account supervisor for Ignite Health.

Clifton Wong has been appointed associate creative director/art of interactive communications, responsible for the creation and production of all multimedia projects for all brands.

In addition, Mr. Wong is tasked with mentoring many of the agency's staff to help build a stronger, more creative digital department. He was previously a design director for The Traffic Agency.

**CONSULTING POOL**

**Michael MORGAN-CURRAN**

**IDEA PHARMA MAKES STAFF ADDITION**



Idea Pharma, a firm specializing in market strategy at Phase II of the clinical development process, has appointed Michael Morgan-Curran as a strategist.

Mr. Morgan-Curran is tasked with shaping

and leading new approaches to help clients make better decisions for products across a variety of therapeutic areas. He has 22 years of experience working in the pharmaceutical and consultancy industries.

**Dr. Susan SUPONCIC**

**KANTAR HEALTH APPOINTS GLOBAL MARKET ACCESS VP**



Kantar Health, a healthcare-focused global consultancy and marketing insights company, has named Susan Suponcic, Ph.D., senior VP of global market access.

Dr. Suponcic leads a global practice team that assists pharmaceutical industry clients in incorporating, substantiating, and implementing market access initiatives to capture the value of their innovations and ensure patient access globally.

Dr. Suponcic joins Kantar Health from Johnson & Johnson, where she held strategic roles in both pricing and health economics. She received an M.Sc. in public policy and administration from the London School of Economics and Political Science and a Ph.D. in Managerial Science and Applied Economics from The Wharton School of the University of Pennsylvania.

**CRO POOL**

**Kathy BOHANNON**

**INC RESEARCH ENHANCES PEDIATRIC EXPERTISE**



INC Research, a therapeutically focused contract research organization (CRO), has appointed Kathy Bohannon principal strategist, pediatrics.

Ms. Bohannon is responsible for developing the operational strategy and providing expertise in the design and execution of pediatric studies. She was previously senior director, clinical trial management, with Premier Research Group.

**Dr. Stephen CUTLER**

**Jamie MACDONALD**

**KENDLE ANNOUNCES SUCCESSION PLAN**



Global full-service CRO Kendle has announced that Senior VP and Chief Operating Officer Stephen Cutler, Ph.D., will become president and CEO, effective May 1.

Dr. Cutler succeeds Candace Kendle, Pharm.D., who continues as Kendle's chairman. He holds a doctorate in philosophy from the University of Sydney in Australia and an MBA

from the University of Birmingham in the United Kingdom.

As part of the May 1 succession plan, Jamie Macdonald will succeed Dr. Cutler as senior VP and chief operating officer.

Mr. Macdonald joins the company after 16 years at Quintiles, where he most recently served as senior VP and head of global project management.

## Dr. Roger HAYES

### FORMER SCHERING-PLOUGH EXECUTIVE JOINS CETERO



Cetero Research, an early-stage CRO, has named Roger Hayes, Ph.D., president, bioanalytical operations. Dr. Hayes joins Cetero after 10 years as director of bioanalytical at Schering-Plough Research Institute, part of Merck Research Laboratories.

He has a Ph.D. in organic chemistry from the University of Adelaide in Australia.

## Dr. Stephen MURRAY

### CLINILABS NAMES MEDICAL CHIEF



Clinilabs, an early-phase and specialty CRO, has named Stephen Murray, M.D., Ph.D., chief medical officer, leading the company's CNS specialty unit.

Dr. Murray was the chief medical officer for several biotech companies involved in the development of drugs for the treatment of depression, cognitive impairment associated with schizophrenia, and Alzheimer's disease, among others.

He received an M.D. and a Ph.D. from the Medical University of South Carolina, where he worked under a National Institutes of Health (NIH) research training grant.

## Dr. Dan WENG

### MEDPACE ADDS TO GLOBAL DEVELOPMENT LEADERSHIP



Medpace has appointed Dan Weng, M.D., VP, rest of world, with responsibility for driving global growth for the CRO in Asia, the Pacific Rim, Latin America, and South Africa.

Dr. Weng has 25 years of clinical experience, including executive positions with various contract research organizations. He received an M.A. in healthy planning, policy, and management from Leeds University in the United Kingdom and a doctor of medicine from Tongji Medical University in China.

In addition, he is a Ph.D. candidate in bio-engineering from Strathclyde University in Glasgow.

## ► MEDICAL-EDUCATION POOL

### Ken (Kenneth) KORBER

#### REACHMD BOLSTERS MEDICAL EDUCATION TEAM



ReachMD, a provider of professional medical news, information, and education services, has appointed Ken (Kenneth) Korber VP of continuing medical education, with responsibility for further expansion of this integral business unit.

Mr. Korber most recently served as senior director of strategic development at CE Outcomes.

## ► SERVICE POOL

### William BROWN

#### David GANZ

#### Barbara RICE

#### Annette VELOTTO

#### ESSRX NAMES NEW OFFICERS



Event Support Services Rx (ESSRx) has announced a number of leadership changes. ESSRx is the parent company of satellite broadcast services provider Advantage Broadcast Solutions; AV Solutions, a provider of audio-visual equipment rentals to pharmaceutical companies; and Total Health Rewards, a provider of PhRMA-compliant, medically relevant items and textbook fulfillment services for the pharmaceutical industry.

William Brown, an Emmy and Telly award-winning executive producer and director, has been appointed a director of business development for ESSRx. Mr. Brown most recently worked in event and broadcast production at Dyventive Events.



David Ganz has been named chief marketing officer. Mr. Ganz has been managing director of Total Health Rewards since its acquisition by ESSRx in 2006.

He holds an MBA from the Baruch/Mount Sinai Health Care Administration Program at Baruch College, part of the City University of New York (CUNY).

Barbara Rice has joined ESSRx as an executive producer. She was an account director at Cardinal Health in the healthcare marketing group responsible for continuing medical education grant proposal submissions and management.

Annette Velotto has been promoted to chief

operating officer of ESSRx, from her previous role as managing director of AV Solutions. Ms. Velotto has 25 years of experience in operations and event planning, 20 of which have been in medical education. She received an M.S. in education from Springfield College in Massachusetts.

## Dave HAMMOND

### QPHARMA NAMES MARKETING VP



Dave Hammond has joined regulatory and compliance solutions provider QPharma as VP of sales and marketing.

Mr. Hammond previously served as VP of sales and marketing for Porzio Pharmaceutical Services and J. Knipper & Co.

## David URBAN

### OLSON RESEARCH GROUP APPOINTS CLIENT SERVICES HEAD



Olson Research Group, a provider of healthcare marketing research and data collection services, has named David Urban VP of client services, working with the company's business development team to oversee client relationships and ensure they receive superior strategic guidance and support at all levels of project execution.

Mr. Urban was most recently VP of enrollment at Eastern University.

## Dr. Angelina VILLARREAL

### GfK CUSTOM RESEARCH ADDS VP, MULTICULTURAL RESEARCH



Information and consultancy service provider GfK Custom Research North America has appointed Angelina Villarreal, Ph.D., VP, multicultural research.

Dr. Villarreal partners with multicultural experts from each of GfK's business units to develop, implement, and measure marketing research strategies for the fast-growing Hispanic, Asian-American, and African-American consumer segments.

Dr. Villarreal was most recently VP of research at Creative Response and Research.

She earned an M.A. in economics from Universidad Autónoma de Nuevo León in Mexico and a Ph.D. in business administration with a major in consumer behavior and a minor in applied statistics from the University of Pittsburgh. <sup>PV</sup>



USE YOUR QR CODE READER  
OR GO TO  
[bit.ly/PV0411-Pool](http://bit.ly/PV0411-Pool)



## ▶ BIOTECHNOLOGY POOL

### Anthony CATALDO

#### GENESIS BIOPHARMA SELECTS CEO

Genesis Biopharma, a biotechnology company developing targeted cancer therapies, has named Anthony Cataldo president and CEO. Mr. Cataldo succeeds Robert Brooke, who continues to serve as a strategic advisor to Genesis. Mr. Cataldo has served as chairman and CEO of Oxis International.

### Dr. Margaret DILLON

### Dr. Robert TRESSLER

#### CELLERANT STRENGTHENS SENIOR MANAGEMENT

Cellerant Therapeutics, a biotechnology company developing hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has appointed Margaret Dillon, Ph.D., VP of regulatory affairs. Dr. Dillon was previously VP of regulatory affairs at CV Therapeutics, now Gilead Sciences.

In other moves, Cellerant has named Robert Tressler, Ph.D., VP of research and development. Dr. Tressler is responsible for managing all aspects of Cellerant's research and development activities. He most recently served as executive director of research at Geron.

### Stephen POTTER

#### FORMER GENZYME VP JOINS OSIRIS THERAPEUTICS

Stephen Potter has joined Osiris Therapeutics as senior VP of operations and corporate development. Mr. Potter was previously senior VP of corporate and business development at Genzyme. He holds an MBA from Harvard Business School.

Osiris is a stem cell company developing products to treat conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas.

## ▶ BIOPHARMACEUTICAL POOL

### Stephen BRADY

#### 3-V BIOSCIENCES PROMOTES BUSINESS CHIEF

3-V Biosciences has promoted Stephen Brady to chief business officer. Mr. Brady joined 3-V in 2010 as VP, corporate development, strategy and operations. He received an LL.M. from New York University School of Law. 3-V Biosciences is a privately held biopharma company focused on therapeutics that target host cell factors required for infection.

### Dr. John CURNUTTE

#### PORTOLA APPOINTS R&D VP

Portola Pharmaceuticals has appointed John Cur-

nutte, M.D., Ph.D., executive VP, research and development. Dr. Curnutte oversees all R&D operations, including discovery research, development, clinical operations, and regulatory affairs.

Dr. Curnutte was most recently CEO of 3-V Biosciences. He received a Ph.D. in biological chemistry and an M.D., both from Harvard Medical School. Portola discovers and develops therapeutics for cardiovascular and inflammatory diseases.

### Dr. Ursula FRITSCH

#### JENNEREX APPOINTS REGULATORY VP

Jennerex, a clinical-stage biotherapeutics company focused on the development of targeted oncolytic products to treat cancer, has named Ursula Fritsch, Pharm.D., VP, regulatory affairs.

Dr. Fritsch is responsible for developing global regulatory strategies and managing all aspects of regulatory affairs for Jennerex's pipeline product candidates.

Dr. Fritsch was previously VP of global regulatory affairs and compliance for Anthera Pharmaceuticals. She received a doctor of pharmacy from Creighton University.

### David GREENWOOD

### Dr. Hoyoung HUH

#### GERON UNVEILS NEW LEADERSHIP

Geron has implemented a new leadership structure that reflects the biopharmaceutical company's progression into midstage clinical development of multiple product candidates for the treatment of cancer and chronic degenerative diseases.

Chief Financial Officer David Greenwood has been appointed president and interim CEO. Mr. Greenwood succeeds Thomas Okarma, Ph.D., M.D., who continues as a consultant to Geron.

Director Hoyoung Huh, M.D., Ph.D., has been named executive chairman of Geron's board, replacing Alexander Barkas, Ph.D., who has moved to the role of lead independent director. Dr. Huh is working closely with Mr. Greenwood and Geron's senior management to advance product-oriented strategies and collaboration-based company growth.

### Lawrence ROSANIA

#### ANTHERA APPOINTS GLOBAL REGULATORY VP

Anthera Pharmaceuticals, a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal autoimmune responses and inflammation, has named Lawrence Rosania VP of global regulatory affairs and compliance.

Mr. Rosania joins Anthera after 12 years as an independent consultant. He holds an M.S. in chemistry from Drexel University and an M.S. in organizational dynamics from the University of Pennsylvania.

## ▶ SPECIALTY POOL

### Dr. Mohan KABADI

### Celina SCHOLL

### Dr. Monil SHAH

#### VENTRUS APPOINTS CLINICAL DEVELOPMENT STAFF

Ventrus Biosciences, a specialty company developing gastrointestinal products, has announced the completion of its clinical development staffing. Ventrus has contracted Mohan Kabadi, Ph.D., as head of pharmaceutical product development and manufacturing.

Dr. Kabadi is responsible for the supply of active pharmaceutical ingredients, as well as development of the extended-release forms of Diltiazem cream. Dr. Kabadi's 20 years of experience includes stints at Bristol-Myers Squibb, Novartis, Pfizer, Fausling, and Roche.

Celina Scholl has been appointed clinical project manager. Ms. Scholl has drug development experience from Novartis and Merck and, most recently, GlaxoSmithKline (GSK) Biologicals.

Monil Shah, Pharm.D., has been named VP, clinical research and development. Dr. Shah was most recently director of clinical strategic planning at Celgene. Dr. Shah has a doctorate in pharmacy from Rutgers University.

## ▶ DEVICE/DIAGNOSTIC POOL

### Erik MILLER

#### ASPENBIO EXPANDS MARKETING LEADERSHIP

AspenBio Pharma, an emerging company developing novel human in vitro diagnostics, has named Erik Miller VP, marketing and business development. Mr. Miller is focused on the company's commercial planning efforts, including preclinical field testing of the AppyScore diagnostic system.

Mr. Miller has been consulting with AspenBio since October 2010 and previously served as VP, business development and marketing, for Radix Biosolutions. He received an MBA from the University of North Carolina.

## ▶ CRO POOL

### Sue ROBINSON

#### PREMIER RESEARCH HIRES PATIENT RECRUITMENT DIRECTOR

Pharmaceutical services company Premier Research Group has named Sue Robinson director of patient recruitment. Ms. Robinson is providing operational oversight of Premier Research's feasibility team and partnering with project teams to build patient recruitment and retention plans. **PV**



**4-6 May 2011 | Bangalore, India**  
**Bangalore International Exhibition Centre**

**India's Largest International Biotech Gathering**

BioPartnering India (BPI) in conjunction with Bangalore INDIA BIO (BIB) is now acknowledged as India's most sought after biotech event. Affordable Innovation is the way forward and in this context it is advantage India.

**Get Involved!**

[www.techvision.com/bpi](http://www.techvision.com/bpi)

PRODUCED BY:



POWERED BY:



IN COLLABORATION WITH:



**May 24-26, 2011**  
**The Meritage Resort**  
**Napa, California, USA**



**C21**  
**BioVentures™**

**Rise to the Challenge, Seize the Opportunity**

As 2011 progresses there are both new opportunities and new challenges for biotech companies, pharmaceutical partners and investors. C21 provides a platform to network with your peers, learn from new business models and pre-schedule face-to-face meetings with the partners and investors you need to succeed.

**Get Involved!**

[www.techvision.com/c21](http://www.techvision.com/c21)

PRODUCED BY:



POWERED BY:



HOSTED BY:

